[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641836":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":10,"centralContacts":36,"locations":42,"responsibleParty":57,"collaborators":10,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":10,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":10,"studyType":73,"phases":10,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"The First Affiliated Hospital of Xinxiang Medical College","OTHER",[8,15,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Young healthy controls",null,"Subjects included individuals aged 25 to 35 years classified as Hamilton-Norwood Class I, who had no family history of alopecia, no comorbid scalp disorders, and no exposure to anti-alopecia therapies, hormonal treatments, or chemical hair processing within the preceding 6 months.",[13,14],"Other: Collection of ~2 × 12 mm scalp tissue","Other: Single-cell sequencing and spatial transcriptome sequencing",{"label":16,"type":10,"description":17,"interventionNames":18},"Young patients with AGA","Patients included individuals aged 25 to 35 years with a confirmed diagnosis of Hamilton-Norwood Grade III, who were free of other forms of alopecia or concurrent scalp disorders, and had no exposure to relevant pharmacological treatments or chemical hair processing within the preceding 6 months.",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Aged healthy controls","Subjects included individuals aged older than 60 years classified as Hamilton-Norwood Class I, who had no family history of alopecia, no concurrent scalp disorders, and no exposure to anti-alopecia therapies, hormonal treatments, or chemical hair processing within the preceding 6 months.",[13,14],{"label":24,"type":10,"description":25,"interventionNames":26},"Aged patients with AGA","Patients included individuals aged older than 60 years with a confirmed diagnosis of Hamilton-Norwood Grade III, who were free of other forms of alopecia or concurrent scalp disorders, and had no exposure to relevant pharmacological treatments or chemical hair processing within the preceding 6 months.",[13,14],[28,32],{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"Collection of ~2 × 12 mm scalp tissue","In the AGA group, scalp tissue samples were concurrently harvested from the affected balding area (vertex, Hamilton-Norwood III vertex) and an unaffected non-balding area (the central occipital region along the interauricular line). In healthy controls, scalp tissue was harvested solely from the occipital region.",[20,24,9,16],{"type":6,"name":33,"description":34,"armGroupLabels":35,"otherNames":10},"Single-cell sequencing and spatial transcriptome sequencing","Spatial Transcriptomics Sequencing Samples were embedded in OCT, cryosectioned (10 μm), fixed with methanol, and subjected to H\\&E staining. After permeabilization (14 min) and RNA capture, libraries were constructed and sequenced on the Xenium platform (sequencing depth ≥ 5 million reads per sample).\n\nSingle-Cell Sequencing Samples were minced and enzymatically digested using Collagenase IV, Dispase II, and DNAse I, followed by erythrocyte lysis, filtering, and resuspension. Single-cell suspensions were prepared with a cell viability ≥ 90% and a clump rate \\\u003C 5%. Sequencing was performed on the 10x Genomics platform (sequencing depth ≥ 10,000 reads per cell).",[20,24,9,16],[37],{"name":38,"role":39,"phone":40,"phoneExt":10,"email":41},"Wenjie Ren","CONTACT","8618937302619","157121431@qq.com",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":10},"The First Affiliated Hospiatl of Henan Medical University","RECRUITING","Xinxiang","Henan","453003","China","CN",{"type":52,"coordinates":53},"Point",[54,55],113.80151,35.19033,{"lat":55,"lon":54},{"type":58,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100641836","multi-omics-insights-into-androgenetic-alopecia-100641836",false,"NCT07603544","Multi-Omics Insights Into Androgenetic Alopecia","Multi-Omics Analysis of the Hair Follicle Microenvironment in Androgenetic Alopecia for Mechanistic Study and Target Identification","Inclusion Criteria:\n\n* Age and Gender: Males aged 25-30 or 60-65 years.\n* Diagnosis: Patient Group: Diagnosed by a physician with Hamilton-Norwood Stage III androgenetic alopecia (AGA). Healthy Control Group: Healthy scalp with no signs of hair loss.\n* Medication and Treatment History: No use of anti-hair loss medications (e.g., minoxidil, finasteride), hormonal drugs, or scalp chemical treatments (perm or dye) within the last 6 months.\n* Informed Consent: Voluntarily signed and provided written informed consent.\n\nExclusion Criteria:\n\n* Scalp Conditions: Presence of other types of alopecia (besides AGA) or active scalp diseases (e.g., psoriasis, dermatitis, infections).\n* Medical History: History of keloids or coagulation disorders.\n* Systemic Diseases: Major underlying conditions, including severe cardiovascular\u002Fcerebrovascular diseases, immune system disorders, or malignant tumors.\n* Allergies: Known hypersensitivity to local anesthetics.\n* Prior Clinical Trials: Participation in any other clinical trials within 3 months prior to screening.\n* Other Factors: Any other conditions deemed unsuitable for participation by the investigator.",true,"MALE","20 Years","65 Years",{"count":71,"type":72},12,"ESTIMATED","OBSERVATIONAL","This study utilizes a multi-omics approach to systematically characterize the cellular heterogeneity and spatial architecture of the hair follicle microenvironment in patients with androgenetic alopecia (AGA). Our primary aim is to elucidate the key mechanisms driving hair follicle stem cell (HFSC) exhaustion and to identify potential therapeutic targets. Investigators will collect six groups of scalp tissue samples, which include healthy controls and AGA patients (stratified into younger and older cohorts). By integrating spatial transcriptomics, single - cell sequencing data, investigators will map aberrant cell subpopulations and their complex interaction networks. Furthermore, the identified core targets will be functionally validated using patient-derived organoids and animal models. Expected outcomes include the identification of 3-5 critical cell subpopulations and the discovery of 8-10 disease-associated targets. Additionally, investigators will establish an integrated clinical-omics-validation database, providing a robust theoretical foundation for the precision diagnosis and treatment of AGA.",[76],"Androgenetic Alopecia (AGA)",[78,79],"single-cell RNA sequencing","spatial transcriptomics","2026-06-11",{"date":82,"type":83},"2026-06-15","ACTUAL",{"date":85,"type":83},"2026-03-08",{"date":87,"type":72},"2027-03",{"name":5,"class":6},1]